Episcleral plaque brachytherapy for retinoblastoma

Thomas E. Merchant, Ciara J. Gould, Matthew Wilson, Nathan E. Hilton, Carlos Rodriguez-Galindo, Barrett G. Haik

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background. The purpose of this study was to report our experience using episcleral plaque brachytherapy (EPBRT) to treat retinoblastoma and to demonstrate its applicability in multimodality treatment. Procedure. We treated 26 tumors in 25 eyes from a group of 21 children with unilateral (n = 4) or bilateral (n = 17) retinoblastoma. The group comprised 8 girls and 13 boys; the median age was 25 months (range: 2-64 months) at the time of EPBRT. Iodine-125 (125I) was used for all applications. The median dose was 44 Gy (range: 35-47.6 Gy). EPBRT was administered primarily at the time of relapse after primary chemotherapy of radiation therapy. Results. For eyes treated with EPBRT, the eye preservation rate was 15/25 with a median follow-up of 47 months (range: 2-198 months); the lesion control rate was 25/26 with a median follow-up of 13 months (range: 1-140 months). The median time to additional whole-eye treatment after EPBRT was 12 months (range: 2-105 months). Conclusions. Similar to previously reported series, EPBRT shows a high rate of successful tumor control as a primary treatment for retinoblastoma, as well as a secondary therapy at the time of relapse. EPBRT also allows for a clinically significant delay in the time to additional measures for the affected eye. Therefore, EPBRT should be considered as a form of local ophthalmic therapy that avoids or delays the use of external-beam radiotherapy, especially for patients primarily treated with chemotherapy who might require consolidation therapy.

Original languageEnglish (US)
Pages (from-to)134-139
Number of pages6
JournalPediatric Blood and Cancer
Volume43
Issue number2
DOIs
StatePublished - Aug 1 2004

Fingerprint

Retinoblastoma
Brachytherapy
Radiotherapy
Therapeutics
Recurrence
Drug Therapy
Iodine
Neoplasms

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Hematology
  • Pediatrics, Perinatology, and Child Health

Cite this

Merchant, T. E., Gould, C. J., Wilson, M., Hilton, N. E., Rodriguez-Galindo, C., & Haik, B. G. (2004). Episcleral plaque brachytherapy for retinoblastoma. Pediatric Blood and Cancer, 43(2), 134-139. https://doi.org/10.1002/pbc.20094

Episcleral plaque brachytherapy for retinoblastoma. / Merchant, Thomas E.; Gould, Ciara J.; Wilson, Matthew; Hilton, Nathan E.; Rodriguez-Galindo, Carlos; Haik, Barrett G.

In: Pediatric Blood and Cancer, Vol. 43, No. 2, 01.08.2004, p. 134-139.

Research output: Contribution to journalArticle

Merchant, TE, Gould, CJ, Wilson, M, Hilton, NE, Rodriguez-Galindo, C & Haik, BG 2004, 'Episcleral plaque brachytherapy for retinoblastoma', Pediatric Blood and Cancer, vol. 43, no. 2, pp. 134-139. https://doi.org/10.1002/pbc.20094
Merchant TE, Gould CJ, Wilson M, Hilton NE, Rodriguez-Galindo C, Haik BG. Episcleral plaque brachytherapy for retinoblastoma. Pediatric Blood and Cancer. 2004 Aug 1;43(2):134-139. https://doi.org/10.1002/pbc.20094
Merchant, Thomas E. ; Gould, Ciara J. ; Wilson, Matthew ; Hilton, Nathan E. ; Rodriguez-Galindo, Carlos ; Haik, Barrett G. / Episcleral plaque brachytherapy for retinoblastoma. In: Pediatric Blood and Cancer. 2004 ; Vol. 43, No. 2. pp. 134-139.
@article{112d33e648d944f29ae8d626c1aefae9,
title = "Episcleral plaque brachytherapy for retinoblastoma",
abstract = "Background. The purpose of this study was to report our experience using episcleral plaque brachytherapy (EPBRT) to treat retinoblastoma and to demonstrate its applicability in multimodality treatment. Procedure. We treated 26 tumors in 25 eyes from a group of 21 children with unilateral (n = 4) or bilateral (n = 17) retinoblastoma. The group comprised 8 girls and 13 boys; the median age was 25 months (range: 2-64 months) at the time of EPBRT. Iodine-125 (125I) was used for all applications. The median dose was 44 Gy (range: 35-47.6 Gy). EPBRT was administered primarily at the time of relapse after primary chemotherapy of radiation therapy. Results. For eyes treated with EPBRT, the eye preservation rate was 15/25 with a median follow-up of 47 months (range: 2-198 months); the lesion control rate was 25/26 with a median follow-up of 13 months (range: 1-140 months). The median time to additional whole-eye treatment after EPBRT was 12 months (range: 2-105 months). Conclusions. Similar to previously reported series, EPBRT shows a high rate of successful tumor control as a primary treatment for retinoblastoma, as well as a secondary therapy at the time of relapse. EPBRT also allows for a clinically significant delay in the time to additional measures for the affected eye. Therefore, EPBRT should be considered as a form of local ophthalmic therapy that avoids or delays the use of external-beam radiotherapy, especially for patients primarily treated with chemotherapy who might require consolidation therapy.",
author = "Merchant, {Thomas E.} and Gould, {Ciara J.} and Matthew Wilson and Hilton, {Nathan E.} and Carlos Rodriguez-Galindo and Haik, {Barrett G.}",
year = "2004",
month = "8",
day = "1",
doi = "10.1002/pbc.20094",
language = "English (US)",
volume = "43",
pages = "134--139",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Episcleral plaque brachytherapy for retinoblastoma

AU - Merchant, Thomas E.

AU - Gould, Ciara J.

AU - Wilson, Matthew

AU - Hilton, Nathan E.

AU - Rodriguez-Galindo, Carlos

AU - Haik, Barrett G.

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Background. The purpose of this study was to report our experience using episcleral plaque brachytherapy (EPBRT) to treat retinoblastoma and to demonstrate its applicability in multimodality treatment. Procedure. We treated 26 tumors in 25 eyes from a group of 21 children with unilateral (n = 4) or bilateral (n = 17) retinoblastoma. The group comprised 8 girls and 13 boys; the median age was 25 months (range: 2-64 months) at the time of EPBRT. Iodine-125 (125I) was used for all applications. The median dose was 44 Gy (range: 35-47.6 Gy). EPBRT was administered primarily at the time of relapse after primary chemotherapy of radiation therapy. Results. For eyes treated with EPBRT, the eye preservation rate was 15/25 with a median follow-up of 47 months (range: 2-198 months); the lesion control rate was 25/26 with a median follow-up of 13 months (range: 1-140 months). The median time to additional whole-eye treatment after EPBRT was 12 months (range: 2-105 months). Conclusions. Similar to previously reported series, EPBRT shows a high rate of successful tumor control as a primary treatment for retinoblastoma, as well as a secondary therapy at the time of relapse. EPBRT also allows for a clinically significant delay in the time to additional measures for the affected eye. Therefore, EPBRT should be considered as a form of local ophthalmic therapy that avoids or delays the use of external-beam radiotherapy, especially for patients primarily treated with chemotherapy who might require consolidation therapy.

AB - Background. The purpose of this study was to report our experience using episcleral plaque brachytherapy (EPBRT) to treat retinoblastoma and to demonstrate its applicability in multimodality treatment. Procedure. We treated 26 tumors in 25 eyes from a group of 21 children with unilateral (n = 4) or bilateral (n = 17) retinoblastoma. The group comprised 8 girls and 13 boys; the median age was 25 months (range: 2-64 months) at the time of EPBRT. Iodine-125 (125I) was used for all applications. The median dose was 44 Gy (range: 35-47.6 Gy). EPBRT was administered primarily at the time of relapse after primary chemotherapy of radiation therapy. Results. For eyes treated with EPBRT, the eye preservation rate was 15/25 with a median follow-up of 47 months (range: 2-198 months); the lesion control rate was 25/26 with a median follow-up of 13 months (range: 1-140 months). The median time to additional whole-eye treatment after EPBRT was 12 months (range: 2-105 months). Conclusions. Similar to previously reported series, EPBRT shows a high rate of successful tumor control as a primary treatment for retinoblastoma, as well as a secondary therapy at the time of relapse. EPBRT also allows for a clinically significant delay in the time to additional measures for the affected eye. Therefore, EPBRT should be considered as a form of local ophthalmic therapy that avoids or delays the use of external-beam radiotherapy, especially for patients primarily treated with chemotherapy who might require consolidation therapy.

UR - http://www.scopus.com/inward/record.url?scp=3042838762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042838762&partnerID=8YFLogxK

U2 - 10.1002/pbc.20094

DO - 10.1002/pbc.20094

M3 - Article

VL - 43

SP - 134

EP - 139

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -